| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Introduction: There is immense current interest in the effects of thyroid hormones on bone. This is largely due to concern that patients on thyroxine replacement therapy are at increased risk of developing osteoporosis; this concern follows a number of reports describing reduced bone mineral density in this group of patients. The issue is, however, uncertain and the purpose of this review is (i) to summarize what is known about the effects of thyroid hormones on bone at both an experimental and clinical level and (ii) to try to reach a greater understanding of the problem and its implications for patient management.
Bone biology: Bone remodelling requires the tightly coupled actions of osteoclasts and osteoblasts. A normal bone remodelling cycle takes approximately 200 days. Each cycle begins with activation of cells which become osteoclasts and start resorbing bone. This phase lasts for about 50 days and is terminated
This article has been cited by other articles:
|
|
 |
|
  A. T. Soliman, M. Omar, A. E. Awwa, M. M. Rizk, R. K. El Alaily, and E. M. A. Bedair Linear Growth, Growth-Hormone Secretion and IGF-I Generation in Children with Neglected Hypothyroidism Before and After Thyroxine Replacement J Trop Pediatr, October 1, 2008; 54(5): 347 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Morimura, K. Tsunekawa, T. Kasahara, K. Seki, T. Ogiwara, M. Mori, and M. Murakami Expression of Type 2 Iodothyronine Deiodinase in Human Osteoblast Is Stimulated by Thyrotropin Endocrinology, April 1, 2005; 146(4): 2077 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. A. Gouveia, M. A. Christoffolete, C. R. Zaitune, J. M. Dora, J. W. Harney, A. L. Maia, and A. C. Bianco Type 2 Iodothyronine Selenodeiodinase Is Expressed throughout the Mouse Skeleton and in the MC3T3-E1 Mouse Osteoblastic Cell Line during Differentiation Endocrinology, January 1, 2005; 146(1): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. S. Freitas, A. S. Moriscot, V. Jorgetti, A. G. Soares, M. Passarelli, T. S. Scanlan, G. A. Brent, A. C. Bianco, and C. H. A. Gouveia Spared bone mass in rats treated with thyroid hormone receptor TR{beta}-selective compound GC-1 Am J Physiol Endocrinol Metab, November 1, 2003; 285(5): E1135 - E1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Fitts, R. M. Klein, and C. A. Powers Estrogen and Tamoxifen Interplay with T3 in Male Rats: Pharmacologically Distinct Classes of Estrogen Responses Affecting Growth, Bone, and Lipid Metabolism, and Their Relation to Serum GH and IGF-I Endocrinology, October 1, 2001; 142(10): 4223 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Yen Physiological and Molecular Basis of Thyroid Hormone Action Physiol Rev, July 1, 2001; 81(3): 1097 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Raval-Pandya, L. P. Freedman, H. Li, and S. Christakos Thyroid Hormone Receptor Does Not Heterodimerize with the Vitamin D Receptor but Represses Vitamin D Receptor-Mediated Transactivation Mol. Endocrinol., September 1, 1998; 12(9): 1367 - 1379. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. M. Fitts, R. M. Klein, and C. A. Powers Comparison of Tamoxifen Effects on the Actions of Triiodothyronine or Growth Hormone in the Ovariectomized-Hypothyroid Rat J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 392 - 402. [Abstract] [Full Text]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
